• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » N-acetylcysteine Shows Promise in Treatment of Co-Occurring PTSD and SUD

N-acetylcysteine Shows Promise in Treatment of Co-Occurring PTSD and SUD

January 1, 2017
Colleen Ryan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Colleen Ryan, MD. Dr. Ryan has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.  

Review of: Back SE et al. A double-blind, randomized, controlled pilot trial of N-acetylcysteine in veterans with post traumatic stress disorder and substance use disorder. J Clin Psychiatry, dx.doi.org/10.4088/JCP.15m10239.

Study type: Double-blind, ­randomized, controlled trial

Post-traumatic stress disorder (PTSD) is the most common psychiatric disorder in veterans who seek treatment at the VA, and substance use disorder (SUD) is a common comorbid condition. While SSRIs can be effective for PTSD symptoms, they don’t treat SUD well.

N-acetylcysteine (NAC) is an antioxidant approved for the treatment of acetaminophen overdose and pulmonary disease, and it has been used in psychiatry for patients with trichotillomania and gambling, among other conditions. Neurochemically, NAC normalizes synaptic glutamate transmission, and ­hypothetically such transmission is disordered in both PTSD and SUD. Therefore, researchers decided to try the medication in a group of veterans with PTSD and SUD.

Thirty-five veterans aged 18–65 from the Ralph H. Johnson VA Medical Center were enrolled; they all met DSM-IV criteria for SUD and PTSD. After at least one week of sobriety, they were randomly assigned to double-blind treatment with either NAC or placebo. The active treatment group received 2,400 mg of NAC daily for 8 weeks. Both groups attended a cognitive behavioral therapy–based outpatient program that met 5 days per week during the study. All patients were assessed with standard research scales for PTSD symptoms, such as the Clinician-Administered PTSD scale (CAPS), and the PTSD Checklist Military (PCL-M); they were also assessed for depression and substance craving. The study was funded by several government agencies, including the Department of Veterans Affairs and the National Institute for Drug Addiction.

Results
Over the course of 8 weeks, patients in the NAC group (N = 13 after dropouts) improved significantly on all measures (p < 0.05), whereas those assigned to placebo (N = 14) improved on only one measure: the CAPS re-experiencing subscale. By week 8, the NAC group had reductions of 46% in the CAPS and 32% on the PCL-M, while the placebo group had reductions of 25% and 3% respectively. There was an 81% reduction in craving in the NAC group compared to 32% in the placebo group. Adverse effects were mild, with the most common being dry mouth and heartburn.

TCPR’s Take
The pilot study has some limitations: Its sample size was small, and it lacked any measure of whether quality of life was improved by symptom reduction. Nonetheless, the symptom improvement for both PTSD and substance craving in the NAC group were impressive.

Practice implications
Given the lack of effective treatments for co-occurring PTSD and SUD, it’s reasonable to try NAC at 2,400 mg/day for such patients. The side effects are minimal, and the improvements in symptoms may be significant.
General Psychiatry
KEYWORDS research-update
    Colleen Ryan, MD.

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Take The CME Post-Test for Adult ADHD, TCPR, January 2017
    N-acetylcysteine Shows Promise in Treatment of Co-Occurring PTSD and SUD
    How to Treat Adult ADHD
    ADHD Overdiagnosis
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2637648401.jpg
      General Psychiatry

      Psychopharm Secrets: Coming Off Meds

      There’s a hidden placebo response to watch for when patients stop meds on their own.
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.